Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...
Rutgers neuroscientist Peng Jiang and his neuroscience colleague Mengmeng Jin have made a discovery they say could reshape ...
An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.
The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...
Scientists have uncovered a surprising mechanism by which a brain enzyme called OTULIN controls the expression of tau, the ...
13hon MSN
Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says
An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...
MedPage Today on MSN
Highly Anticipated Alzheimer's Trials Yield Disappointing Results for GLP-1 Drug
The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...
Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in ...
16hon MSN
Analysts, investors say Alzheimer's miss adds to Novo's challenges, but fundamentals intact
Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...
GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...
FOX 32 Chicago on MSN
How to spot signs of Alzheimer's disease in a loved one
Choose a calm moment, listen first and give the person time to share how they feel. Here are some other tips on how to help a ...
We break down the current state of frontotemporal dementia, from bvFTD to PPA, and why 'promising' therapies are still far ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results